ASH 2020 | Deep and durable responses with brexucabtagene autoleucel at the one-year follow up of ZUMA-2
Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL discusses the one-year follow-up results of brexucabtagene autoleucel, formerly KTE-X19, use in relapsed/refractory mantle cell lymphoma (MCL) in the Phase II ZUMA-2 trial (NCT02601313). 60 patients were treated with brexucabtagene autoleucel, an anti-CD19 CAR-T cell therapy, and followed up for a minimum of a year. Responses were deep and durable, with an overall response rate over 90% and almost half the participants with ongoing responses at data cutoff. Adverse effects were manageable, results in a promising benefit-risk profile. The results show that brexucabtagene autoleucel in this patient population where curative options are lacking is of significant clinical benefit. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
